Opinion|Videos|April 11, 2025
Determining Follow-Up Approach in Melanoma Based on GEP Risk Level
Author(s)David Cotter, MD, PhD
An expert discusses whether the 31-gene expression profile (GEP) risk classification would change treatment guidelines and how the patient’s GEP risk level would influence the approach to surveillance and follow-up.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Does the 31-GEP risk classification change your treatment guidelines?
- How would you approach surveillance and follow-up with this patient after knowing their GEP risk level?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
2
Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis
3
FDA Accepts Galderma’s BLA Resubmission for Liquid Neuromodulator RelabotulinumtoxinA
4
Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older
5